Project Grant S10OD038264

Award Date 4/1/25
Completion Date 3/31/26
Dollars Obligated $1.8M
Funding Federal Agency
Office of the Director
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) provides $949,116 to the University of South Florida (USF) to acquire a Thermo Fisher Scientific Orbitrap IQ-X mass spectrometer system with a Vanquish Flex UHPLC system. This high-resolution instrument will establish a unique nucleic acid adductomics (NAA) omics capability at USF that is not currently available as a shared resource. The...
This $1,352,820 Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) will fund the acquisition of a novel Orbitrap Astral mass spectrometer at the Massachusetts General Hospital (MGH) in Boston, MA. The high-throughput and high-sensitivity mass spectrometer will enable advanced proteomics research focused on cancer and Alzheimer's disease. The instrument will benefit 13 research projects, providing enhanced capabilities for...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA 93.351 (Research Infrastructure Programs) provides $582,750 to Boston University Medical Campus to acquire an inductively coupled plasma time-of-flight mass spectrometer (ICP-TOF-MS). The advanced instrumentation will be used for ultrafast laser ablation-assisted multi-elemental mapping of high-value clinical and preclinical biospecimens at the university's Center for Biometallomics. The...
This federal Project Grant award of $456,808 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskelastic and Skin Diseases Research program (CFDA 93.846), will fund the development of innovative mass spectrometry imaging (MSI) technologies to spatially visualize proteins and glycans in bone and cartilage tissue samples. The project aims to advance understanding of disease progression in osteoarthritis and meniscal injury by...
This $731,896 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) will support novel ion chemistry and instrument development for the characterization of proteins, nucleic acids, and heterogeneous bio-complexes via tandem mass spectrometry. The research aims to extend the utility of mass spectrometry and tandem mass spectrometry in top-down biopolymer characterization, as well as in the mass...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $1,105,757 to the University of Rochester to acquire a state-of-the-art TIMSTOF HT mass spectrometry and liquid chromatography system. This advanced instrumentation will significantly enhance the proteomic analysis capabilities of the University of Rochester Mass Spectrometry Resource Laboratory, enabling high-throughput, high-resolution quantitative...
This $1,829,859 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development and validation of a new "Scalable Single-Cell Mass Spectrometry" (SCEMAS) proteomics platform. The goal is to enable high-sensitivity mass spectrometry analysis of protein changes associated with aging, such as in neurons and cerebrospinal fluid samples. The 4-year award to the University of Maryland, College Park will address technical limitations that...
This federal Project Grant award from the Department of Health and Human Services, National Institutes of Health under the Research Infrastructure Programs (CFDA 93.351) provides $750,000 to Case Western Reserve University to acquire a state-of-the-art, integrated mass spectrometry-based system for hydrogen/deuterium exchange (HDX-MS) studies on complex protein systems. This advanced instrumentation will support a large community of over 30 biomedical researchers across multiple institutions...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $771,190 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to acquire an upgraded LC-MS system to support medicinal chemistry research and development. The current aging LC-MS system has become increasingly unreliable, requiring frequent and costly repairs. The new instrumentation will enable MGH to maintain analytical and bioanalytical chemistry...
This $719,476 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS Biomedical Research and Research Training, CFDA 93.859) will support the acquisition of a state-of-the-art MALDI-QTOF mass spectrometer for imaging mass spectrometry (IMS) at the University of California, Irvine (UC Irvine). The instrument will enable high-resolution spatial phenotyping of biomolecules such as proteins, lipids, and metabolites across multiple interdisciplinary research...

This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director, under the NIH Research Infrastructure Programs (CFDA 93.351), provides $1,759,412 to the Buck Institute for Research on Aging to acquire a Bruker TIMSTOF FLEX MALDI-2 mass spectrometry system for spatial molecular imaging.

The instrument will enable the Buck Institute and a collaborative network of 18 independent investigators from 8 institutions to spatially resolve molecular signatures, including proteins, glycans, lipids, and metabolites, in human and animal tissues and organoids down to a 5-10 micron resolution. This advanced mass spectrometry platform will support ongoing and future research projects examining key issues of human health and healthspan, including the biology of aging, age-related diseases like Alzheimer's and Huntington's, and other conditions such as Parkinsonism, osteoarthritis, kidney disease, and metabolic disorders. The award period is from April 1, 2025 to March 31, 2026.

Generated 4/8/25, 3:30 AM